Lupin Launches Generic Hypertension Drug in U.S., Secures Exclusivity
Event summary
- Lupin launched Azilsartan Medoxomil Tablets (40mg and 80mg) in the U.S. on June 17, 2026, following FDA approval.
- The product is bioequivalent to Edarbi® and is indicated for treating hypertension in adults.
- Lupin is the exclusive first-to-file, eligible for 180-day generic drug exclusivity.
- Edarbi® had estimated annual U.S. sales of $53.5 million (IQVIA MAT April 2026).
The big picture
Lupin's launch of Azilsartan Medoxomil Tablets underscores its strategy of expanding its generic portfolio in the U.S. cardiovascular market. The move comes amid increasing pressure on branded hypertension drugs, with generics capturing a growing share of prescriptions. Lupin's first-to-file status provides a temporary advantage, but sustaining market position will depend on pricing and distribution efficiency.
What we're watching
- Market Exclusivity
- How Lupin will leverage its 180-day exclusivity to capture market share from Edarbi®.
- Revenue Impact
- Whether Lupin can achieve significant revenue from the $53.5 million addressable market.
- Competitive Response
- The pace at which competitors may introduce their own generic versions post-exclusivity.
Related topics